Majocchi's granuloma
Methodology & AI Transparency ⓘ
Majocchi's granuloma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as B35.8, Majocchi's granuloma falls under Infections & Antivirals management, where bacterial/fungal culture with in Majocchi's granuloma (B35.8: antimicrobial susceptibility testing) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Majocchi's granuloma uses ICD-10 B35.8 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Clinicians assessing Majocchi's granuloma focus on tissue neutrophil/lymphocyte recruitment [Majocchi's granuloma B35.8] and targeted history.
- 4 Top reported side effects / signs: Key Infections & Antivirals biomarkers for Majocchi's granuloma (B35.8): Complete Blood Count in Majocchi's granuloma (B35.8: (WBC & Differential)) & C-Reactive Protein / in Majocchi's granuloma (B35.8: Procalcitonin) (Resolution to baseline (B35.8)).
Ask our AI Specialists anything about Majocchi's granuloma
What Is Majocchi's granuloma?
Designated in federal medical registries as B35.8, Majocchi's granuloma falls under Infections & Antivirals management, where bacterial/fungal culture with in Majocchi's granuloma (B35.8: antimicrobial susceptibility testing) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Majocchi's granuloma (B35.8) alters infections & antivirals homeostasis through tissue neutrophil/lymphocyte recruitment [Majocchi's granuloma B35.8]; clinical remission targets C-Reactive Protein / in Majocchi's granuloma (B35.8: Procalcitonin) within Resolution to baseline (B35.8).
Common Symptoms & Clinical Signs
- • Presentation of Majocchi's granuloma (B35.8): regional lymph node in Majocchi's granuloma (B35.8: tenderness or acute)
- • Secondary Majocchi's granuloma clinical sign: acute fever, chills, in Majocchi's granuloma (B35.8: malaise, and myalgias)
- • Symptom flares in Majocchi's granuloma correlating with Complete Blood Count in Majocchi's granuloma (B35.8: (WBC & Differential)) deviation outside WBC 4.0 – 10.0 x10^3/uL (B35.8)
- • Functional infections & antivirals impact requiring bacterial/fungal culture with in Majocchi's granuloma (B35.8: antimicrobial susceptibility testing) evaluation (B35.8)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Majocchi's granuloma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B35.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Majocchi's granuloma (B35.8: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B35.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Majocchi's granuloma (B35.8: Procalcitonin) | Resolution to baseline (B35.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Majocchi's granuloma (B35.8: Culture & Sensitivity) | Pathogen clearance / negative test (B35.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Majocchi's granuloma
Treatment selection for Majocchi's granuloma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Majocchi's granuloma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on An Analysis of How Herpes Zoster Pain Affects Health-related Quality of Life of A total of 520 immunocompetent and 172 HSCT individuals with HZ were included. The Clinical journal of pain • 2023-08-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37166199 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Further studies are needed to assess the efficacy of the neutralizing antibody to prevent disease deterioration and its benefits among groups of patients specified by disease course and severity. Antimicrobial agents and chemotherapy • 2022-03-15 • Phase III Randomized Trial | N = 199 | 82/100 | PMID 35191746 ↗ |
Majocchi's granuloma Patient Community & “People Like Me” Threads
Filter Majocchi's granuloma community threads and patient logs by age, biological sex, dosage, and treatment duration.